10-Q: LifeMD Reports Q3 2026 Results: Revenue Down, Losses Widen

LifeMD, Inc. reported a net loss of $4.47 million for Q3 2026, with revenues decreasing to $44.6 million compared to the prior year, driven by lower product sales and increased operating expenses.

Summary

• LifeMD reported a net loss of $4.47 million for the third quarter of 2026, compared to a net loss of $3.64 million in the same period last year.
• Total revenues for the quarter decreased by 7% to $44.6 million, primarily due to a $3.2 million decrease in telehealth product revenue.
• Cost of telehealth revenue increased by 17% to $8.2 million, leading to a decrease in gross profit to $36.4 million and a lower gross profit margin of 81.5% from 85.2%.
• Total operating expenses decreased by 7% to $40.8 million, mainly due to reduced selling and marketing expenses, but were partially offset by increases in general and administrative and other operating expenses.
• The company ended the quarter with $21.9 million in cash and cash equivalents, a decrease from $36.8 million at the end of 2025.
• The company has identified material weaknesses in its internal control over financial reporting and is implementing a remediation plan.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reported net loss, increased operating expenses, and a decrease in revenue, despite efforts to expand services and partnerships.

Positives

• Telehealth subscription revenue remained stable, indicating continued demand for recurring care services.
• Selling and marketing expenses decreased by 18% due to reduced online marketing spend.
• The company has secured a new $12.5 million loan facility with Avenue Capital Group to support operations.
• The company continues to expand its B2B telehealth partnerships, including collaborations with AT&T, Novo Nordisk, and Antares Pharma.
• The company is actively working on remediating material weaknesses in its internal controls.

Negatives

• Net loss widened to $4.47 million in Q3 2026 from $3.64 million in Q3 2025.
• Total revenues decreased by 7% to $44.6 million, driven by a significant drop in telehealth product revenue.
• Cost of telehealth revenue increased by 17%, leading to a decrease in gross profit margin to 81.5% from 85.2%.
• General and administrative expenses increased by 6%, driven by higher compensation and taxes/licenses.
• Working capital decreased significantly to a negative $12.4 million from a positive $5.4 million.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• Changes in market acceptance of products and competitive pricing.
• Ability to successfully commercialize products profitably and maintain customer/supplier relationships.
• Risks associated with technological developments, including AI, and cybersecurity threats.
• Potential for material weaknesses in internal control over financial reporting to lead to misstatements.
• Need to raise additional funds in the future.
• Impact of industry regulation, including on compounded medications and digital healthcare.
• General economic conditions, including inflation and potential recession.
• Business interruptions from geopolitical events or disease outbreaks.

Future Outlook

The company expects that its existing cash of $21.9 million as of September 30, 2026, and its new Loan and Security Agreement with Avenue Capital Group will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least the next 12 months. The company is also focused on increasing revenue growth through its recurring revenue subscription-based sales model and new telehealth offerings.

Management Comments

• The company expects that its existing cash as of September 30, 2026 of $21.9 million and its Loan and Security Agreement with Avenue will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these unaudited consolidated financial statements.
• Management believes that the integration of our patient care center with our technology platform strengthens patient engagement, supports adherence to prescribed therapies, and contributes to sustained patient satisfaction as we scale.
• Management believes these efforts will support the continued execution of the remediation efforts in 2026 and into 2027.

Industry Context

StockSavvy.ai notes that LifeMD's performance reflects broader trends in the telehealth sector, including increased competition, evolving regulatory landscapes, and a shift towards integrated care models. The company's focus on specialty care programs like weight management and women's health aligns with industry growth areas, but the reported revenue decline and increased costs highlight the challenges in scaling profitably within this competitive environment.

Comparison to Industry Standards

• The gross profit margin of 81.5% for Q3 2026 is strong compared to many retail or product-based businesses, but the increase in cost of telehealth revenue as a percentage of sales (18.5% vs 14.8%) indicates pressure on margins.
• The company's operating loss from continuing operations of $4.47 million in Q3 2026, representing 10% of revenue, is a concern. Many successful telehealth companies aim for profitability or at least a path to it within a similar revenue range.
• The significant increase in accounts payable ($37.7 million) and inventory ($10.3 million) suggests a shift in operational model, potentially to a principal-based revenue recognition, which requires careful working capital management compared to an agent model.
• The company's focus on subscription revenue is a positive industry trend, aiming for predictable income streams, but the decline in product revenue indicates a potential weakness in that segment.

Corporate Governance

Legal Proceedings

• A purported shareholder class action complaint (Johnston v. LifeMD, Inc., et al.) alleging violations of the Securities Exchange Act of 1934 and Rule 10b-5 has been transferred to the Southern District of New York.
• Four putative shareholder derivative complaints have been filed alleging violations of the Exchange Act, breach of fiduciary duties, and other claims against officers and directors. These have been consolidated and stayed pending a ruling on the motion to dismiss in the class action.

Related Party Transactions

• During the nine months ended September 30, 2025, the company paid CloudBoson Technologies Pvt. Ltd. (owned by WorkSimpli's Chief Software Engineer) approximately $2.9 million for software development services.
• Will Febbo (Board member) entered into a consulting agreement for investor relations and strategic business development, compensated with RSUs.
• Naveen Bhatia (former Board member) entered into consulting agreements for strategic business development, compensated with RSUs.
• Brian Schreiber (relative of CEO, Logistics & Fulfillment Advisor) received an adjusted employment agreement with an annual base salary increase to $240,000 and a modified bonus agreement.

Stakeholder Impact

• Shareholders: The net loss, revenue decline, and identified material weaknesses in internal controls may negatively impact investor confidence and stock price.
• Creditors: The company has secured new debt financing, but the negative working capital and ongoing losses may increase perceived risk.
• Employees: Continued focus on operational efficiency and remediation of internal controls is crucial for long-term stability.
• Customers: The company continues to emphasize patient experience and access to care, with ongoing efforts to improve service delivery.

Next Steps

• Continue to implement and test remediation plans for material weaknesses in internal controls.
• Focus on increasing revenue growth through subscription-based models and new telehealth offerings.
• Manage working capital effectively, particularly with increased inventory and receivables.
• Monitor the effectiveness of new B2B partnerships and their contribution to revenue.
• Continue to expand insurance coverage for virtual primary care services.

Key Dates

Recommendation

While LifeMD is making strategic moves in partnerships and expanding its service offerings, the reported decline in revenue, widening net loss, and significant increase in operating expenses are concerning. The identified material weaknesses in internal controls also present a risk. The new financing provides some short-term liquidity, but the path to profitability remains unclear. A 'hold' recommendation is appropriate pending signs of revenue stabilization, improved cost management, and successful remediation of internal control deficiencies.

Keywords

telehealth, virtual care, pharmacy services, revenue, net loss, operating expenses, stock-based compensation, internal controls